|Laura Saward, Ph.D.|
Senior Vice President, Antibody Therapeutics Business Unit Head
Dr. Saward joined Emergent BioSolutions in 2014 through the acquisition of Cangene Corporation and has served as senior vice president, antibody therapeutics business unit lead since April 2017. Prior to this position, Dr. Saward was vice president of research and development from April 2014 to April 2017. Before joining Emergent, Dr. Saward held various leadership roles at Cangene including chief scientific officer and vice president of research and development from April 2012 to April 2014, and senior director of bioanalytical research from October 2010 to April 2012, which provided her the opportunity to direct the licensure of multiple products for commercial markets and government contracts for the Strategic National Stockpile.
Prior to joining Cangene, Dr. Saward’s career included positions in start-ups, mid-size and larger pharma companies including Cardiovascular Sciences Inc., Viventia Biotech, Syntex and Johnson & Johnson.
Dr. Saward received her B.Sc. from the University of Guelph and Ph.D. from the Faculty of Medicine at the University of Manitoba. She completed her Post-doctoral Fellowship at Robarts Research Institute, University of Western Ontario. Dr. Saward maintains strong ties to academia through her adjunct professor position at University of Manitoba, Department of Medical Microbiology and Infectious Diseases, and as a member of many key boards in Manitoba including Research Manitoba.